Translating insights from the cancer genome into clinical practice

Lynda Chin; Joe W. Gray

doi:10.1038/nature06914

Translating insights from the cancer genome into clinical practice

Lynda Chin, Joe W. Gray

Research output: Contribution to journal › Review article › peer-review

246 Scopus citations

Abstract

Cancer cells have diverse biological capabilities that are conferred by numerous genetic aberrations and epigenetic modifications. Today's powerful technologies are enabling these changes to the genome to be catalogued in detail. Tomorrow is likely to bring a complete atlas of the reversible and irreversible alterations that occur in individual cancers. The challenge now is to work out which molecular abnormalities contribute to cancer and which are simply 'noise' at the genomic and epigenomic levels. Distinguishing between these will aid in understanding how the aberrations in a cancer cell collaborate to drive pathophysiology. Past successes in converting information from genomic discoveries into clinical tools provide valuable lessons to guide the translation of emerging insights from the genome into clinical end points that can affect the practice of cancer medicine.

Original language	English (US)
Pages (from-to)	553-563
Number of pages	11
Journal	Nature
Volume	452
Issue number	7187
DOIs	https://doi.org/10.1038/nature06914
State	Published - Apr 3 2008
Externally published	Yes

ASJC Scopus subject areas

General

Access to Document

10.1038/nature06914

Cite this

@article{e32bdedbac6d4c76920aa0f3bde24510,

title = "Translating insights from the cancer genome into clinical practice",

abstract = "Cancer cells have diverse biological capabilities that are conferred by numerous genetic aberrations and epigenetic modifications. Today's powerful technologies are enabling these changes to the genome to be catalogued in detail. Tomorrow is likely to bring a complete atlas of the reversible and irreversible alterations that occur in individual cancers. The challenge now is to work out which molecular abnormalities contribute to cancer and which are simply 'noise' at the genomic and epigenomic levels. Distinguishing between these will aid in understanding how the aberrations in a cancer cell collaborate to drive pathophysiology. Past successes in converting information from genomic discoveries into clinical tools provide valuable lessons to guide the translation of emerging insights from the genome into clinical end points that can affect the practice of cancer medicine.",

author = "Lynda Chin and Gray, {Joe W.}",

note = "Funding Information: Acknowledgements We thank R. DePinho, A. Futreal, P. Mischel, A. Kimmelman, K.-K. Wong, W. Hahn and K. Polyak for discussions and critical reading of the manuscript. This work was supported in part by the US Department of Energy, the Office of Science, the Office of Biological and Environmental Research, the National Institutes of Health and the National Cancer Institute.",

year = "2008",

month = apr,

day = "3",

doi = "10.1038/nature06914",

language = "English (US)",

volume = "452",

pages = "553--563",

journal = "Nature",

issn = "0028-0836",

publisher = "Nature Publishing Group",

number = "7187",

}

TY - JOUR

T1 - Translating insights from the cancer genome into clinical practice

AU - Chin, Lynda

AU - Gray, Joe W.

N1 - Funding Information: Acknowledgements We thank R. DePinho, A. Futreal, P. Mischel, A. Kimmelman, K.-K. Wong, W. Hahn and K. Polyak for discussions and critical reading of the manuscript. This work was supported in part by the US Department of Energy, the Office of Science, the Office of Biological and Environmental Research, the National Institutes of Health and the National Cancer Institute.

PY - 2008/4/3

Y1 - 2008/4/3

N2 - Cancer cells have diverse biological capabilities that are conferred by numerous genetic aberrations and epigenetic modifications. Today's powerful technologies are enabling these changes to the genome to be catalogued in detail. Tomorrow is likely to bring a complete atlas of the reversible and irreversible alterations that occur in individual cancers. The challenge now is to work out which molecular abnormalities contribute to cancer and which are simply 'noise' at the genomic and epigenomic levels. Distinguishing between these will aid in understanding how the aberrations in a cancer cell collaborate to drive pathophysiology. Past successes in converting information from genomic discoveries into clinical tools provide valuable lessons to guide the translation of emerging insights from the genome into clinical end points that can affect the practice of cancer medicine.

AB - Cancer cells have diverse biological capabilities that are conferred by numerous genetic aberrations and epigenetic modifications. Today's powerful technologies are enabling these changes to the genome to be catalogued in detail. Tomorrow is likely to bring a complete atlas of the reversible and irreversible alterations that occur in individual cancers. The challenge now is to work out which molecular abnormalities contribute to cancer and which are simply 'noise' at the genomic and epigenomic levels. Distinguishing between these will aid in understanding how the aberrations in a cancer cell collaborate to drive pathophysiology. Past successes in converting information from genomic discoveries into clinical tools provide valuable lessons to guide the translation of emerging insights from the genome into clinical end points that can affect the practice of cancer medicine.

UR - http://www.scopus.com/inward/record.url?scp=41649109807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41649109807&partnerID=8YFLogxK

U2 - 10.1038/nature06914

DO - 10.1038/nature06914

M3 - Review article

C2 - 18385729

AN - SCOPUS:41649109807

SN - 0028-0836

VL - 452

SP - 553

EP - 563

JO - Nature

JF - Nature

IS - 7187

ER -

Translating insights from the cancer genome into clinical practice

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this